Prospective observational study of treatment and outcomes for patients with newly diagnosed follicular lymphoma
PETReA Plus is a UK-based observational study generating critical data from a wide range of FL patients. The study will help clinicians and patients with FL to make more informed, personalized decisions about their treatment in the future. Learn more about how PETReA Plus is contributing to the largest global FL databank and biorepository below.
Program:
Lead researcher:
Institution:
Time period:
Funding partners:
PETReA Plus
Dr Kim Linton
Manchester University, UK
Sep ’24 – Sep ’28
Blood Cancer UK & Joyce and Norman Freed Charitable Trust
Despite significant advances in treatment, follicular lymphoma (FL) remains incurable and relapse is inevitable for most patients. Accurate prospective prediction of risk is currently only feasible in around 50 to 60% of cases using the best prognostic tools. Being able to predict risk is central to developing more effective therapies and selecting the best and most appropriate treatments for patients.
PETReA Plus is the only study in the world that is prospectively collecting outcomes of initial management from all people with newly diagnosed FL.
Unique results of this study, such as whether outcomes are influenced by the order in which treatments are given and how best to match treatments to certain patient groups, cannot be obtained from current clinical trials. PETReA Plus will therefore address gaps in our knowledge that will be crucial for improving cure rates in FL and providing new knowledge to inform next-generation treatments.
PETReA Plus is a transformative project poised to revolutionize FL management. It aims to develop better treatments that cure FL patients and avoid unnecessary toxic therapies. It is a visionary UK observational sub-study of PETReA; an international trial focused on understanding the best use of rituximab, an antibody treatment, to improve outcomes according to risk groups.
Looking at both PETReA and PETReA Plus, results on around 1500 patients will be analyzed to provide information on the full spectrum of FL diagnoses, including newly diagnosed FL patients who cannot take part in the main trial (PETReA). Importantly, PETReA Plus data will also form part of the Follicular Lymphoma Foundation’s Precision Medicine Program (PMP) registry, a global effort that shares the aims and ambitions of PETReA Plus.
The study is led by Dr Kim Linton, an internationally leading clinician and researcher in FL. She works at The Christie in Manchester, the largest comprehensive cancer center in Europe with a reputation for delivering excellence in clinical care and research across all cancer types. Investigators running the study at NHS Centers are all leaders in the field, with a track record of successfully delivering this type of study.
Put together, the results of the PETReA and PETReA Plus studies will provide the largest global data repository in FL; this is hugely important in an under researched disease area like FL where achieving a cure will only be possible if we work together.
The data generated will provide information on different outcomes being linked with different diagnoses and different treatment regimens. This will help clinicians and patients with FL to make more informed, personalized decisions about their treatment. Through the questionnaires collected during the study, PETReA Plus will provide a unique patient voice and narrative about their FL experience to shape better supportive care and inform future generations of patients.
The project is being co-funded by Blood Cancer UK and the Joyce and Norman Freed Charitable Trust, both of whom share our belief in the transformational nature of this study.
We’d love to hear from you if you’re interested in learning more about the FLF and our initiatives. We welcome your feedback, support, and collaboration in any way you can.
If you want to find out more about the FLF and any of our research programs, please contact us at info@theflf.org.
